MARKET

PRRUF

PRRUF

Immutep Ltd
OTCPK
0.050
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
0.050
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.334
52 WEEK LOW
0.040
MARKET CAP
73.69M
P/E (TTM)
-1.3089
1D
5D
1M
3M
1Y
5Y
1D
IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action – Contact Levi & Korsinsky
TipRanks · 05/13 04:15
JPMorgan Entities Exit Substantial Holder Status in Immutep
TipRanks · 05/10 22:33
Largest borrow rate increases among liquid names
TipRanks · 05/08 16:50
Immutep receives noncompliance notification from Nasdaq
TipRanks · 04/30 14:06
Immutep Faces Nasdaq Bid-Price Deficiency but Retains Listings as It Seeks Compliance
TipRanks · 04/30 01:23
Immutep Halts Key Lung Cancer Trial but Pipeline Advances on Solid Cash Base
TipRanks · 04/30 00:30
Immutep to Present New Eftilagimod Alfa Data at ASCO 2026
TipRanks · 04/22 00:17
Unusually active option classes on open April 15th
TipRanks · 04/15 13:40
More
About PRRUF
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including OTCPK: PRRUF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRRUF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRRUF stock methods without spending real money on the virtual paper trading platform.